{"id":"W4282918298","doi":"10.1358/dot.2022.58.6.3400572","title":"Bimekizumab for psoriasis","year":2022,"lang":"en","type":"article","venue":"Drugs of today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Secukinumab; Psoriasis; Ustekinumab; Tolerability; Adalimumab; Adverse effect; Dermatology; Immunology; Immune system; Population; Internal medicine; Tumor necrosis factor alpha; Psoriatic arthritis","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002138325,0.0001059152,0.0002159697,0.00009287397,0.0002504033,0.000002659986,0.0002090102,0.00006225929,0.001641214],"category_scores_gemma":[0.00002562137,0.00009942431,0.0001739207,0.0001080009,0.00004375229,0.00002992885,0.00009045308,0.00006765816,0.00007615561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000361986,"about_ca_system_score_gemma":0.00004143249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004814853,"about_ca_topic_score_gemma":0.00000234691,"domain_scores_codex":[0.9992818,0.00009855236,0.0001861246,0.0001896965,0.00003355436,0.0002102831],"domain_scores_gemma":[0.9994529,0.0001792435,0.0001013457,0.000222598,0.00003294465,0.0000109004],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002767705,0.001249591,0.002491524,0.00008403315,0.001822731,0.000006441995,0.005335229,0.00007404503,0.2384884,0.01456357,0.1264149,0.6067019],"study_design_scores_gemma":[0.005016774,0.0006074563,0.001754692,0.000006671706,0.0002536638,0.00001820564,0.001280159,0.000003923407,0.2748497,0.001155835,0.7148029,0.0002500268],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842106,0.004532663,0.00007271987,0.0006333242,0.002904766,0.00052008,0.000884968,0.00008648548,0.006154385],"genre_scores_gemma":[0.98905,0.00002514944,0.0002491116,0.00008338087,0.00003802028,0.0002419412,0.0002862275,0.00001543768,0.0100107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6064518,"threshold_uncertainty_score":0.9992714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01460619210585043,"score_gpt":0.24055590479578,"score_spread":0.2259497126899296,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}